These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15608560)

  • 1. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
    King BP; Khan TI; Aithal GP; Kamali F; Daly AK
    Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
    Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
    Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose.
    Tanira MO; Al-Mukhaini MK; Al-Hinai AT; Al Balushi KA; Ahmed IS
    Community Genet; 2007; 10(1):32-7. PubMed ID: 17167248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
    Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
    Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
    Lee SJ; Jang YJ; Cha EY; Kim HS; Lee SS; Shin JG
    Br J Clin Pharmacol; 2010 Aug; 70(2):213-21. PubMed ID: 20653674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
    Cavallari LH; Vaynshteyn D; Freeman KM; Wang D; Perera MA; Takahashi H; Drozda K; Patel SR; Jeong H
    Pharmacogenet Genomics; 2013 Apr; 23(4):228-31. PubMed ID: 23376925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
    Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
    Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
    Veenstra DL; Blough DK; Higashi MK; Farin FM; Srinouanprachan S; Rieder MJ; Rettie AE
    Clin Pharmacol Ther; 2005 May; 77(5):353-64. PubMed ID: 15900281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.